Actionable news
All posts from Actionable news

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans

► Stock Price ► Stock List ► TSX ► Fertilizer

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans

MISSISSAUGA, ON, April 22, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in his current role to ensure a smooth transition of responsibilities, and the Company has commenced a formal search process for a new CFO.

"Norm has been an important part of Cipher's growth and success since 2007, and on behalf of the Board and all the employees, I want to thank him for his service to the Company and wish him well in retirement," said Shawn O'Brien, President & Chief Executive Officer. "We have built a strong finance team and capabilities to support the growth of the business and our evolution to an integrated dermatology company. Norm will work closely with the finance team to ensure a seamless and successful transition."Along with the strong finance team he has built, will ensure a seamless transition."

"I am very proud of what we have accomplished at Cipher and thankful to have spent almost 10 years with the company," said Mr. Evans. "With a growing portfolio of marketed products, a pipeline of late-stage assets, and a strong financial foundation, Cipher is well positioned for future growth. I wish Shawn and the team continued success."

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly growing specialty pharmaceutical dermatology company with a diversified portfolio of commercial-stage products with the goal of becoming the most customer-centric dermatology company in North America.

Cipher completed seven transactions in 2015, including the acquisition of Innocutis and its nine branded dermatology products, to build its U.S. commercial presence, expand its Canadian dermatology franchise and broaden its pipeline. Cipher is well-capitalized to drive long-term, sustained earnings growth by leveraging its proven clinical development capabilities and efficient commercial execution. For more information, visit

Forward-Looking Statements

Statements made in this news release may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form, Form 40-F and other filings with Canadian and U.S. securities regulatory authorities. These factors include, but are not limited to our ability to enter into in-licensing, development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on three products; integration difficulties and other risks if we acquire or inlicense technologies or product candidates; reliance on third parties for the marketing of our products; the product approval process is highly unpredictable; the timing of completion of clinical trials; reliance on third parties to manufacture our products; we may be subject to product liability claims; unexpected product safety or efficacy concerns may arise; generate revenue from a limited number of distribution and supply agreements; the pharmaceutical industry is highly competitive; requirements for additional capital to fund future operations; dependence on key managerial personnel and external collaborators; no assurance that we will receive regulatory approvals in the U.S., Canada or any other jurisdictions; limitations on reimbursement in the healthcare industry; limited reimbursement for products by government authorities and third-party payor policies; various laws pertaining to health care fraud and abuse; reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the industry in which it operates; foreign currency risk; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent law; litigation in the pharmaceutical industry concerning the manufacture and supply of novel versions of existing drugs that are the subject of conflicting patent rights; inability to protect our trademarks from infringement; shareholders may be further diluted; volatility of our share price; a significant shareholder; we do not currently intend to pay dividends; and our operating results may fluctuate significantly; we may be unsuccessful in evaluating material risks involved in complete and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; operations in the U.S.; and inability to meet covenants on our credit facilities.. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian or U.S. securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.

SOURCE Cipher Pharmaceuticals Inc.

%SEDAR: 00020415E

For further information: Investors: In Canada: Craig Armitage, LodeRock Advisors, (416) 347-8954,; In the United States: Thomas Hoffmann, The Trout Group LLC, (646) 378-2931,; Media: Mike Beyer, Sam Brown Inc., (312) 961-2502,

CO: Cipher Pharmaceuticals Inc.

CNW 10:00e 22-APR-16

To receive a free e-mail notification whenever Cipher Pharmaceuticals Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Annual report - English - April 7, 2016

Notice of meeting - English - April 6, 2016
Management information circular - English - April 6, 2016